Close

Teva Pharma (TEVA) Announces Data on TEV-48125 Phase 2B Migraine Program Published in Lancet

September 30, 2015 8:08 AM EDT Send to a Friend
Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) announced today that Lancet Neurology published online, as back-to-back articles, the results from two ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login